INTRODUCTION: This prospective study aimed to develop a robust and clinically applicable method to identify patients with high-risk early-stage lung cancer and then to validate this method for use in future translational studies. METHODS: Three published Affymetrix microarray data sets representing 680 primary tumors were used in the survival-related gene selection procedure using clustering, Cox model, and random survival forest analysis. A final set of 91 genes was selected and tested as a predictor of survival using a quantitative real-time polymerase chain reaction-based assay using an independent cohort of 101 lung adenocarcinomas. RESULTS: The random survival forest model built from 91 genes in the training set predicted patient survival in an independent cohort of 101 lung adenocarcinomas, with a prediction error rate of 26.6%. The mortality risk index was significantly related to survival (Cox model p < 0.00001) and separated all patients into low-, medium-, and high-risk groups (hazard ratio = 1.00, 2.82, 4.42). The mortality risk index was also related to survival in stage 1 patients (Cox model p = 0.001), separating patients into low-, medium-, and high-risk groups (hazard ratio = 1.00, 3.29, 3.77). CONCLUSIONS: The development and validation of this robust quantitative real-time polymerase chain reaction platform allows prediction of patient survival with early-stage lung cancer. Utilization will now allow investigators to evaluate it prospectively by incorporation into new clinical trials with the goal of personalized treatment of patients with lung cancer and improving patient survival.
RCT Entities:
INTRODUCTION: This prospective study aimed to develop a robust and clinically applicable method to identify patients with high-risk early-stage lung cancer and then to validate this method for use in future translational studies. METHODS: Three published Affymetrix microarray data sets representing 680 primary tumors were used in the survival-related gene selection procedure using clustering, Cox model, and random survival forest analysis. A final set of 91 genes was selected and tested as a predictor of survival using a quantitative real-time polymerase chain reaction-based assay using an independent cohort of 101 lung adenocarcinomas. RESULTS: The random survival forest model built from 91 genes in the training set predicted patient survival in an independent cohort of 101 lung adenocarcinomas, with a prediction error rate of 26.6%. The mortality risk index was significantly related to survival (Cox model p < 0.00001) and separated all patients into low-, medium-, and high-risk groups (hazard ratio = 1.00, 2.82, 4.42). The mortality risk index was also related to survival in stage 1 patients (Cox model p = 0.001), separating patients into low-, medium-, and high-risk groups (hazard ratio = 1.00, 3.29, 3.77). CONCLUSIONS: The development and validation of this robust quantitative real-time polymerase chain reaction platform allows prediction of patient survival with early-stage lung cancer. Utilization will now allow investigators to evaluate it prospectively by incorporation into new clinical trials with the goal of personalized treatment of patients with lung cancer and improving patient survival.
Authors: Dennis A Wigle; Igor Jurisica; Niki Radulovich; Melania Pintilie; Janet Rossant; Ni Liu; Chao Lu; James Woodgett; Isolde Seiden; Michael Johnston; Shaf Keshavjee; Gail Darling; Timothy Winton; Bobby-Joe Breitkreutz; Paul Jorgenson; Mike Tyers; Frances A Shepherd; Ming Sound Tsao Journal: Cancer Res Date: 2002-06-01 Impact factor: 12.701
Authors: A Bhattacharjee; W G Richards; J Staunton; C Li; S Monti; P Vasa; C Ladd; J Beheshti; R Bueno; M Gillette; M Loda; G Weber; E J Mark; E S Lander; W Wong; B E Johnson; T R Golub; D J Sugarbaker; M Meyerson Journal: Proc Natl Acad Sci U S A Date: 2001-11-13 Impact factor: 11.205
Authors: M E Garber; O G Troyanskaya; K Schluens; S Petersen; Z Thaesler; M Pacyna-Gengelbach; M van de Rijn; G D Rosen; C M Perou; R I Whyte; R B Altman; P O Brown; D Botstein; I Petersen Journal: Proc Natl Acad Sci U S A Date: 2001-11-13 Impact factor: 11.205
Authors: Guoan Chen; Tarek G Gharib; Hong Wang; Chiang-Ching Huang; Rork Kuick; Dafydd G Thomas; Kerby A Shedden; David E Misek; Jeremy M G Taylor; Thomas J Giordano; Sharon L R Kardia; Mark D Iannettoni; John Yee; Philip J Hogg; Mark B Orringer; Samir M Hanash; David G Beer Journal: Proc Natl Acad Sci U S A Date: 2003-10-22 Impact factor: 11.205
Authors: David G Beer; Sharon L R Kardia; Chiang-Ching Huang; Thomas J Giordano; Albert M Levin; David E Misek; Lin Lin; Guoan Chen; Tarek G Gharib; Dafydd G Thomas; Michelle L Lizyness; Rork Kuick; Satoru Hayasaka; Jeremy M G Taylor; Mark D Iannettoni; Mark B Orringer; Samir Hanash Journal: Nat Med Date: 2002-07-15 Impact factor: 53.440
Authors: Guoan Chen; Tarek G Gharib; Chiang-Ching Huang; Dafydd G Thomas; Kerby A Shedden; Jeremy M G Taylor; Sharon L R Kardia; David E Misek; Thomas J Giordano; Mark D Iannettoni; Mark B Orringer; Samir M Hanash; David G Beer Journal: Clin Cancer Res Date: 2002-07 Impact factor: 12.531
Authors: Wei-Hsuan Lo-Ciganic; Julie M Donohue; Joshua M Thorpe; Subashan Perera; Carolyn T Thorpe; Zachary A Marcum; Walid F Gellad Journal: Med Care Date: 2015-08 Impact factor: 2.983
Authors: Ajaya Kumar Reka; Guoan Chen; Richard C Jones; Ravi Amunugama; Sinae Kim; Alla Karnovsky; Theodore J Standiford; David G Beer; Gilbert S Omenn; Venkateshwar G Keshamouni Journal: Carcinogenesis Date: 2014-02-07 Impact factor: 4.944
Authors: So Hee Kim; Guoan Chen; Amanda N King; Chae Kyung Jeon; Paul J Christensen; Lili Zhao; Robert U Simpson; Dafydd G Thomas; Thomas J Giordano; Dean E Brenner; Bruce Hollis; David G Beer; Nithya Ramnath Journal: Lung Cancer Date: 2012-05-06 Impact factor: 5.705